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Abstract Data are scarce on the impact of vertebral
fractures (VFX) on utility. The objective of this study was
to assess the impact of prevalent and incident VFX on
utility in both a patient-based and population-based sample.
Data from the Multiple Outcomes of Raloxifene Evaluation
(MORE) study (n = 550 for prevalent VFX and n = 174
for incident VFX) and the European Prospective Osteo-
porosis Study (EPOS) (n = 236) were used. Utility was
assessed by the index score of the EQ-5D. In the MORE
study, highly statistically significant associations were
found between utility and the presence of prevalent VFX
(p \ 0.001), number of prevalent VFX (p \ 0.001),
severity of prevalent VFX (p \ 0.001), the combination of
number and severity of prevalent VFX (p = 0.001) and
location of prevalent VFX (p = 0.019). The mean utility
was significantly lower among women who suffered an
incident VFX (utility = 0.67) than among women who did
not (utility = 0.77) (p = 0.005), although utility loss was
not significantly different between the two groups
(p = 0.142). In EPOS, the combination of number and
severity of incident VFX was significantly related to utility
(p = 0.030). In conclusion, utility is lower among persons
with prevalent and incident VFX, especially in a patient-
based sample. Utility loss was not significantly different
between women without and with incident VFX.
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Abbreviations
VFX Vertebral fractures
MORE study Multiple Outcomes of Raloxifene Study
EPOS European Prospective Osteoporosis Study
EVOS European Vertebral Osteoporosis Study
BMD Bone mineral density
QALY Quality-adjusted life years
SQ Semi-quantitative
BSQ Binary semi-quantitative
QM Quantitative morphometric
BMI Body mass index
Introduction
Vertebral fractures (VFX) are among the most common
osteoporotic fractures. The prevalence and incidence fig-
ures vary strongly between different studies [1–7]. In a
large European study, the European Vertebral Osteoporosis
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Study (EVOS), the prevalence of radiographically defined
VFX was 12% in both women and men [8]. This study was
continued as the European Prospective Osteoporosis Study
(EPOS), in which the age-standardized incidence of VFX
was estimated at 10.7/1,000 person years in women and
5.7/1,000 person years in men [9]. Both clinical and sub-
clinical VFX are associated with back pain, impaired
physical functioning, and decreased quality of life [1, 3, 4,
7, 10–19].
Quality of life can be assessed by either generic ques-
tionnaires, such as the EQ-5D and SF-36, or disease-
specific questionnaires, such as the Qualeffo-41 and OPAQ
[20]. In addition, some generic questionnaires can be used
to calculate utilities. This is the value attached to a specific
health state, which varies between 0 (representing death)
and 1 (representing perfect health) [20]. Advantages are
that multiple outcomes with different consequences, e.g.,
VFX and hip fracture, can be converted into a single score,
and that this single score can be used to compare different
diseases. Furthermore, utilities can be used to calculate loss
of quality-adjusted life years (QALYs), a measure
increasingly used in cost-effectiveness studies [21].
In the field of osteoporosis, there is a lack of empirical
data on utility after different types of fractures [21]. Only
few studies have assessed the association between VFX
and utility [1, 11, 14, 16–19]. The utility after VFX varied
between 0.20 and 0.85, depending on the time frame,
definition of VFX, and population used. Most studies did
not examine incident VFX, or differentiated between
severity and location of the VFX. Therefore, the objective
of our study was to assess the impact of prevalent and
incident VFX on utility in both a patient-based sample
(from a clinical trial) and a population-based sample (from
a cohort study), and to distinguish between number,
severity and location of VFX.
Methods
Patient-based sample
The Multiple Outcomes of Raloxifene Evaluation (MORE)
study is a double-blind, placebo-controlled, randomized
clinical trial examining the effects of raloxifene in post-
menopausal women. Patients were assigned to study group
1 if they had low bone mineral density (BMD) (T-score
B -2.5) and no more than one mild prevalent VFX (see
Fig. 1). Study group 2 included women with either at least
one moderate VFX or at least two mild VFX in the pres-
ence of low BMD, or at least two moderate fractures
regardless of BMD. To assess the association of prevalent
VFX and utility, baseline EQ-5D data were gathered in
study group 1 (n = 304) and 2 (n = 346) in four European
countries: Belgium, Sweden, The Netherlands, and the
United Kingdom. To assess the association of incident
VFX and utility, only patients from study group 2
(n = 346) were included since only they were scheduled to
have quality of life data gathered at follow-up visits.
Because patients from study group 2 were included in both
the prevalent and incident VFX analyses, the study samples
were not independent.
Population-based sample
EPOS is a cohort study, in which subjects from population-
based registers in 36 centers were recruited. Stratified
random sampling was used with the aim of recruiting a
target number of 50 subjects in each of six 5-year age and
sex bands per center: 50–54, 55–59, 60–64, 65–69, 70–75,
and 75 years and over. Subjects in 29 centers were invited
for a baseline and follow-up radiograph of the thoracic and
lumbar spine, and 12 centers in seven countries (Czech
Republic, Hungary, Italy, Slovakia, Spain, Sweden and
United Kingdom) agreed to participate in the quality of life
study. The quality of life study is a substudy (n = 269),
carried out as a nested case-control study, in which first all
cases with incident VFX were selected (n = 73). It was
then attempted to recruit three controls per case, matched
for age (within 5 years), sex and center: one with a pre-
valent deformity at baseline and two without. In practice,
only 60 and 136 controls were recruited in these two
groups, respectively. Subjects with prevalent VFX were
only included if they also had an incident VFX, or they
were recruited as a matched control, and hence they are not
representative of prevalent VFX in the population. As a
consequence, prevalent VFX could not be analyzed
separately.
Methods of assessing VFX
In the MORE study, spinal radiographs were taken at baseline,
and at 2 and 3 years after baseline. Before randomization,
standardized baseline spinal radiographs were assessed quan-
titatively. Vertebral deformities were assigned to anterior,
central or posterior height loss in comparison with the adjacent
vertebra. Mild prevalent VFX were described as 20–25%
height loss and moderate as 25% height loss or more. Three
different methods were used to assesswhether an incidentVFX
occurredduring follow-up: the semi-quantitative method(SQ),
the binary semi-quantitative method (BSQ), and the quantita-
tive morphometric method (QM) [10, 14]. Radiologists were
blinded to treatment assignment but not to the temporal
sequence of the radiographs. The SQ method was applied to
each participant’s baseline and follow-up radiographs using a
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score of 0 (no fracture), 1.0 (mild), 2.0 (moderate), or 3.0
(severe). A change in SQ score of 1.0 from baseline to follow-
up resulted in BSQ and QM analyses performed on the entire
series of radiographs for the participant. The BSQ analysis was
performed by a second radiologist who rated the fracture as 0
(no fracture) or 1.0 (fracture). For QM, both a 20% height
decrease and a 4-mm absolute vertebral height decrease was
required for an incident fracture to be diagnosed. An incident
VFX was reported only when confirmed by at least two of the
three readings. In EPOS, both baseline and follow-up spinal
radiographs (mean = 3.8 years after baseline) were evaluated
in a single center (Berlin) [12, 22]. Prevalent deformities at
baseline were defined morphometrically using the McClos-
key–Kanis algorithm [23]. Incident VFX were classified both
by qualitative (clinical) radiologist assessment and/or
morphometrically. The morphometric method used required a
vertebra to satisfy criteria for a McCloskey–Kanis deformity
on the second radiograph and, in addition, show a change
(between films) in either anterior, mid or posterior vertebral
height of at least 20% (with the reduction in height being at
least 4 mm).
Utility
Utility was assessed by the EQ-5D in both studies [24]. For
the MORE study, baseline utility and utility at 3 years after
baseline were used. In EPOS, utility was assessed only
once, at 1.9 years (= median) after the second follow-up
(approximately 3.8 + 1.9 = 5.7 years after baseline). The
Study group 1:
- Low BMD and no more than one 
mild prevalent VFX
Study group 2:
- At least one moderate VFX and low 
BMD
- At least two mild VFX and low BMD 
- Two moderate VFX, regardless of  
 BMD
Participated in quality of life study at 
baseline and 3 years (n=190) 
Data on incident VFX available 
(n=190)
Sufficient information for calculating 
utility at baseline and 3 years (174 
women)
Participated in quality of life study at 
baseline (n=297) 
Participated in quality of life study at 
baseline (n=277) 
Data on prevalent VFX available 
(n=296)
Data on prevalent VFX available 
(n=277)
Sufficient information for calculating  
baseline utility (n=280)
Sufficient information for calculating  
baseline utility (n=270)
Prevalent VFX study 
Incident VFX study 
Eligible to participate in EQ-5D 
quality of life study (n=304) a
Eligible to participate in EQ-5D 
quality of life study (n=346) bn=650
n=574
n=573
n=550
Fig. 1 Flow chart MORE
study. a Study group 1
participants from The
Netherlands and United
Kingdom were scheduled to
participate in the EQ-5D quality
of life study. b Study group 2
participants from Belgium,
Sweden, The Netherlands and
United Kingdom were
scheduled to participate in the
EQ-5D quality of life study
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EQ-5D consists of five items representing the domains
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. These can be converted into a single
index score or utility, which summarizes the health state of
a participant. In total, there are 243 different health states
possible. In a UK study, the time trade-off method was
used to derive valuations for 42 health states, which were
subsequently modeled to predict the remaining index
scores [25].
Statistical analyses
The analyses of prevalent and incident VFX, respectively,
with utility were largely performed in the same way. First,
mean utilities and 95% confidence intervals were calcu-
lated for persons without and with VFX. To test whether
the groups were significantly different, Mann–Whitney
U-test and Kruskal–Wallis H-test were used because of the
skewed distribution of utility. In the MORE study, the
influence of number, severity, a combination of number
and severity, and location of VFX on utility was examined
only for prevalent VFX, since power was not sufficient to
analyze these characteristics for incident VFX. In EPOS,
the influence of number, severity and location of VFX was
only examined for incident VFX, while the data were not
available for prevalent VFX.
Because of several baseline differences between women
with and without prevalent VFX in the MORE study,
presence of prevalent VFX was also stratified by median
age, median body mass index (BMI) and history of non-
VFX. Due to power limitations, we did not stratify the
incident VFX analyses.
In the MORE study, change in utility was calculated by
subtracting baseline utility from utility at 3 years in order
to compare loss of utility in women with and without an
incident VFX during follow-up.
The combination of number and severity of VFX in both
studies was calculated as follows: all persons with severe
VFX, all persons with three or more VFX and all persons
with two VFX of which at least one was moderate were
categorized as ‘‘severe osteoporosis’’, and the remainder as
‘‘mild or no osteoporosis’’.
Results
For the prevalent VFX analyses of the MORE study, data
on quality of life were available for 574 women, and data
on prevalent VFX were available for 573 of these women
(see Fig. 1). Baseline utilities could be calculated for 550
women. Non-responders (650–550 = 100 women) were
significantly older (p = 0.01) and had a higher number of
postmenopausal years (p \ 0.001) than responders. For the
incident VFX analyses, data on quality of life and incident
VFX were available for 190 women (see Fig. 1). Baseline
and 3-year utilities could be calculated for 174 women.
Non-responders (346–174 = 172 persons) were signifi-
cantly older (p \ 0.001) and had a higher number of
postmenopausal years (p \ 0.001) than responders. In
EPOS, utilities could be calculated for 63 cases and 173
controls. Non-responders (269–236 = 33 persons) had
significantly more fractures before baseline than responders
(p = 0.032).
In Tables 1 and 2, the baseline characteristics of the
MORE study and EPOS are presented. In the MORE study,
women with prevalent VFX were significantly older, had a
higher BMI, more years since menopause, a lower lumbar
spine BMD, and a higher percentage with a history of non-
VFX than women without prevalent VFX. Furthermore,
women with incident VFX had significantly lower lumbar
spine BMD than women without incident VFX. In EPOS,
no significant baseline differences were found.
In Table 3, it can be seen that the presence of prevalent
VFX (p \ 0.001), an increasing number of prevalent VFX
(p \ 0.001), severity of prevalent VFX (p \ 0.001), and
the combination of number and severity of prevalent VFX
(p = 0.001) were highly significantly associated with
utility in the MORE study. With regard to the location of
the prevalent VFX, the utility scores were significantly
different between women who had only a thoracic VFX,
women who had only a lumbar VFX, and women who had
both a thoracic and lumbar VFX (p = 0.019). However,
when dividing the thoracic and lumbar regions into more
precise locations, no significant differences were found
between the locations (p = 0.853).
In Table 4 the influence of age, BMI and history of non-
VFX on the association between utility and prevalent VFX
is presented. Women with prevalent VFX consistently had
significantly lower baseline utility scores compared to
women without prevalent VFX. The adverse effect of
prevalent VFX on utility was most pronounced among
women having a high BMI.
When comparing all women without incident VFX
(n = 143) during the 3 years of follow-up of the MORE
study to those women who did have an incident VFX
(n = 31), a statistically significant difference was found at
baseline, thus before the incident VFX occurred [utility for
no incident VFX = 0.76 (95%CI: 0.72–0.80); utility for
incident VFX = 0.69 (95%CI: 0.60–0.77); p = 0.021]. In
addition, a highly significant difference after 3 years was
observed [utility for no incident VFX = 0.77 (95%CI:
0.73–0.81); utility for incident VFX = 0.67 (95%CI: 0.58–
0.76); p = 0.005]. However, utility loss during the 3-year
follow-up period was not significantly different between
women without and with incident VFX (p = 0.142).
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In EPOS (Table 5), a significantly lower utility was
observed when combining number and severity of VFX
(p = 0.030). No other significant differences were observed.
Discussion
A lower utility was observed among women with prevalent
VFX as compared with women having no VFX in a
patient-based sample. Although utility was significantly
lower among women who suffered an incident VFX, utility
loss was not significantly different. This indicates that the
occurrence of incident VFX can already be predicted at an
early stage by a worse health state. In a population-based
study, only the combination of number and severity of
incident VFX was significantly related to utility.
In both studies, the lowest utility was found for persons
with incident VFX who already had prevalent VFX. All
persons in our analysis from the MORE study with incident
VFX also had prevalent VFX, since follow-up EQ-5D data
were collected only in women in study group 2 (util-
ity = 0.67). In EPOS, the utility was 0.71 for cases with
incident VFX who also had prevalent VFX. These findings
are consistent with those reported in an earlier EPOS study
which showed that cases with a baseline deformity had
significantly lower utility than controls without a baseline
deformity (p \ 0.001) [12]. Furthermore, in the MORE
study, especially a high BMI in combination with prevalent
VFX had a great impact on utility. An earlier EPOS study
showed that women with lumbar deformity were more
likely to report back pain than those with a thoracic
deformity [26]. In our study, utility was lower in women
Table 1 Baseline characteristics of the MORE study
Prevalent VFX Incident VFXa
No (n = 271) Yes (n = 279) p-valueb No (n = 143) Yes (n = 31) p-valueb
Age (years)c 66.2 ± 5.9 68.8 ± 6.3 \0.001 67.7 ± 6.0 68.8 ± 6.2 0.377
BMI (kg/cm2)c 24.9 ± 3.4 25.6 ± 3.8 0.028 25.5 ± 3.6 25.7 ± 4.1 0.706
Years postmenopausalc 17.8 ± 7.1 21.0 ± 7.8 \0.001 19.8 ± 8.0 20.9 ± 8.1 0.482
Caucasian (%) 267 (98.5%) 275 (98.6%) 1.00 141 (98.6%) 30 (96.8%) 0.479
Lumbar spine BMD (g/cm2)c 0.83 ± 0.14 0.78 ± 0.13 \0.001 0.79 ± 0.13 0.72 ± 0.09 0.010
History of non-VFX (%) 86 (31.7%) 131 (47.0%) \0.001 76 (53.1%) 17 (54.8%) 0.864
a By design, all persons selected for the follow-up study had prevalent vertebral fractures
b Differences in mean were tested with T-test, and in proportion with v2 test
c Mean ± SD
Table 2 Baseline characteristics of EPOSa
Controls without incident VFX Cases with incident VFX
No prevalent
VFX (n = 120)
Prevalent
VFX (n = 53)
All controls
(n = 173)
No prevalent
VFX
(n = 43)
Prevalent
VFX (n = 20)
All cases (n = 63) p-valueb
Age (years)c 64.4 ± 6.8 63.4 ± 7.1 64.1 ± 6.8 63.9 ± 7.5 67.8 ± 6.0 65.2 ± 7.2 0.301
Sex (% female) 95 (79.2%) 39 (73.6%) 134 (77.5%) 35 (81.4%) 14 (70.0%) 49 (77.8%) 0.958
BMI (kg/cm2)c 27.3 ± 4.1 26.5 ± 3.6 27.1 ± 4.0 27.3 ± 3.7 26.0 ± 3.5 26.9 ± 3.7 0.789
Lumbar spine BMDd,e 0.94 (0.88–1.15) 0.97 (0.79–
1.09)
0.95 (0.88–1.11) 0.91 (0.74–
1.00)
0.83 (0.68–
0.96)
0.89 (0.72–0.98) 0.079
Pre-baseline fracture
since age 50 (%)
14 (11.7%) 10 (18.9%) 24 (13.9%) 6 (14.0%) 6 (30.0%) 12 (19.0%) 0.328
a While the EPOS study is a case-control study in which controls were selected to match the cases (with incident VFX) by age, sex and center,
the controls are not representative for the general population. Per case, two controls were selected who did not have a previous vertebral fracture
and one control who did have a previous vertebral fracture
b Comparison: all controls versus all cases with an incident vertebral fracture. Differences in mean were tested with T-test, in median with
Mann–Whitney U test, and in proportion with v2 test
c Mean ± SD
d Median (and interquartile range)
e Only assessed in a subgroup (n = 72)
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with lumbar VFX, but this difference was not statistically
significant.
Most associations between VFX and utility were only
statistically significant in the MORE study, and not in
EPOS. This may be explained by several reasons. First, the
MORE study is a patient-based sample in which the
patients were selected in a clinic. In contrast, the partici-
pants from EPOS, although a relatively small case-control
study which might not be completely representative of the
general population anymore, were selected in the popula-
tion. Therefore, it is likely that more subclinical
(asymptomatic) VFX were included. Second, the time-
frame between incident VFX and assessment of the EQ-5D
instrument is longer in EPOS than in the MORE study. In
the MORE study, the follow-up radiographs were at 2 and
3 years after baseline; in EPOS, the follow-up radiograph
was at a mean of 3.8 years after baseline. Furthermore, in
the MORE study, quality of life was assessed at 3 years
and in EPOS at a median of 1.9 years after the second
follow-up radiograph. Assuming that the incident VFX
occurred in the middle between the two radiographs, this
means that utility was assessed 1.5 years after the incident
VFX in the MORE study, and 3.8 years after the incident
VFX in EPOS. Finally, the sample size was larger in the
MORE study and therefore the MORE study had more
power to detect statistically significant differences.
The most important strength of this study is that it dif-
ferentiates between number, severity and location of VFX,
and that it not only examined prevalent VFX, but also
incident VFX. Therefore, this study contributes to the
Table 3 Association between prevalent vertebral fractures and mean utility (95% CI) in the MORE study
Prevalent VFX Number of persons Utility at baseline p-valuea
Presence of prevalent VFX
No 271 0.82 (0.80–0.85) \0.001
Yes 279 0.73 (0.70–0.76)
Number of prevalent VFXb
0 271 0.82 (0.80–0.85) \0.001
1 122 0.75 (0.71–0.79)
2 65 0.74 (0.68–0.80)
C3 92 0.71 (0.66–0.77)
Most severe prevalent VFXc
No 253 0.82 (0.80–0.85) \0.001
Mild 140 0.77 (0.74–0.80)
Moderate 89 0.70 (0.63–0.76)
Severe 68 0.72 (0.66–0.78)
Combination of number and severity of prevalent VFX
Mild or no osteoporosis 410 0.80 (0.78–0.82) 0.001
Severe osteoporosis 140 0.72 (0.67–0.76)
Location of prevalent VFX (1)b
Thoracic vfx only 136 0.78 (0.74–0.81) 0.019d
Lumbar vfx only 41 0.68 (0.57–0.79)
Thoracic and lumbar VFX 102 0.70 (0.65–0.75)
Location of prevalent VFX (2)e
T4–T6 only 13 0.77 (0.65–0.90) 0.853c
T7–T9 only 45 0.79 (0.74–0.84)
T10–T12 only 51 0.76 (0.70–0.82)
L1–L2 only 30 0.72 (0.60–0.83)
L3–L4 only 6 0.76 (0.62–0.90)
a Differences in means were tested using Mann–Whitney U- and Kruskal–Wallis H-tests
b Mean utility in women with 0, 1 and 2 VFX, thoracic VFX only and lumbar VFX only were also reported in Oleksik et al. [14]
c As assessed by the SQ method which uses a score of 0 (no fracture), 1.0 (mild), 2.0 (moderate), and 3.0 (severe)
d p-value represents comparison among women with prevalent VFX. When adding the women without VFX to these analyses (n = 271;
utility = 0.82; 95% CI: 0.80–0.85), the difference between the groups is statistically significant at p \ 0.001
e The number of persons do not add up to the total number of incident VFX because persons who had incident VFX at two different locations
were not included in this analysis. When adding the women with multiple locations to the analysis (n = 134; utility = 0.70; 95% CI: 0.65–0.75),
the difference between the groups is statistically significant at p \ 0.001
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knowledge on utility in persons with osteoporosis. In
addition, both studies were prospective studies.
A limitation might be that it was not possible to nor-
malize the distribution of utility due to multiple peaks in
order to perform adjusted analyses. However, utilities are
usually presented unadjusted. Because quality of life is
such a broad concept, many factors are part of it and it may
be too strict to adjust for these factors. Baseline differ-
ences, such as BMI, may influence mobility, for example,
and therefore quality of life. However, we did stratify the
analyses on age, BMI and history of non-VFX in order to
examine the influence of these factors on utility.
In the MORE study, only small differences were
observed between one and two prevalent VFX, moderate
and severe prevalent VFX, lumbar VFX and both thoracic
and lumbar VFX (Table 3). Furthermore, there was little
utility loss in women having incident VFX. In EPOS, no
significant differences were observed for incident VFX
(yes/no), number of incident VFX, most severe incident
VFX and location of VFX (Table 5). These results indicate
that the EQ-5D might be less sensitive to change than the
more specific quality of life questionnaires, such as Qual-
effo-41. A disadvantage of the EQ-5D is that it consists of
only five questions, which may make the instrument less
valid for describing the impact of certain diseases. Another
problem might be that only 42 out of 243 health states of
the EQ-5D were derived using the time trade-off method,
and the remaining ones were predicted by modeling these
42 health states. However, the results for the MORE study
might also be explained by a threshold in the impact of
number and severity of VFX on utility, and by the fact that
lumbar VFX are known to have a greater impact than
thoracic VFX. Furthermore, in prevalent VFX it is not clear
Table 4 Influence of age, body mass index and history of non-ver-
tebral fractures on the association between prevalent vertebral
fractures and mean utility (95% CI) in the MORE study
Stratum Prevalent VFX Number of
persons
Utility at
baseline
p-valuea
Age
\67.8 No 159 0.83 (0.79–0.86) \0.001
Yes 116 0.73 (0.69–0.78)
C67.8 No 112 0.81 (0.78–0.85) 0.018
Yes 163 0.73 (0.69–0.77)
BMI
\25.1 No 145 0.83 (0.79–0.86) 0.007
Yes 130 0.78 (0.74–0.81)
C25.1 No 126 0.82 (0.78–0.85) \0.001
Yes 148 0.70 (0.65–0.74)
History of non-VFX
No No 185 0.83 (0.80–0.86) \0.001
Yes 148 0.75 (0.70–0.78)
Yes No 86 0.80 (0.76–0.85) 0.014
Yes 131 0.72 (0.68–0.76)
a Differences in means were tested using Mann–Whitney U-test
Table 5 Association between incident vertebral fractures and mean utility (95% CI) in EPOS
Incident VFX Number of persons Utility 5.7 years after baseline p-valuea
Controls without incident VFX
No prevalent VFX 120 0.82 (0.79–0.85) 0.065b
Prevalent VFX 53 0.80 (0.75–0.85)
All controls 173 0.82 (0.79–0.84)
Cases with incident VFX
No prevalent VFX 43 0.80 (0.73–0.86)
Prevalent VFX 20 0.71 (0.63–0.78)
All cases 63 0.77 (0.72–0.82)
Number of incident VFXc
0 187 0.81 (0.78–0.84) 0.406
1 40 0.78 (0.72–0.83)
C2 9 0.79 (0.68–0.91)
Most severe incident VFXc
No (\20% height loss) 187 0.81 (0.78–0.84) 0.200
Mild (20–25% height loss) 7 0.77 (0.55–1.00)
Moderate (25–40% height loss) 25 0.82 (0.77–0.87)
Severe ([40% height loss) 17 0.71 (0.62–0.81)
Combination of number and severity of incident
VFXc
Mild or no osteoporosis 215 0.81 (0.79–0.83) 0.030
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how long the VFX is present, and this may influence the
impact on utility. The lack of significant effects as
observed in EPOS might be explained by low numbers and
by the inclusion of asymptomatic fractures. Finally, in both
studies, part of the incident VFX might have occurred some
time ago because of the time period between the radio-
graphs. Future research should confirm the sensitivity and
validity of the EQ-5D instrument.
Other limitations were that, for some categories of VFX,
the number of persons was too small to assess the associ-
ation between these categories and utility, and that multiple
tests were carried out increasing the risk of type I error.
Furthermore, we were not able to examine different time
frames as for example in the studies of Johnell et al. and
Tosteson et al. [17, 18]. In the first study, part of the lost
quality of life was regained after 6 months, but after that a
stable reduction was found until 12 months. In the second
study, utility after VFX changed from 0.74 within 1 year
after the fracture to 0.85 after more than 2 years. It would
be interesting to further examine this in future prospective
studies with larger numbers of VFX and shorter intervals
between the VFX and utility assessment. Finally, particu-
larly in the MORE study, it was not possible to calculate
utilities for all participants. Since non-responders were
significantly older, the associations presented here may
have been underestimated.
In conclusion, utility as assessed by the index score of
the EQ-5D is lower among persons with prevalent and
incident VFX, especially in a patient-based sample. Utility
loss was not significantly different between women without
and with incident VFX. The findings of this study may
contribute to the knowledge on the impact of VFX on
utility in the field of osteoporosis.
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